Last Updated: August 9, 2026

List of Excipients in Branded Drug UP AND UP


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for UP AND UP

Last updated: February 28, 2026

What is the excipient strategy for UP AND UP?

UP AND UP, a Walgreens-brand OTC medication, employs a strategic excipient formulation to ensure product stability, efficacy, and shelf life. The excipient composition typically includes inactive ingredients such as binders, fillers, stabilizers, preservatives, and disintegrants. The choice of excipients aims to maximize bioavailability while minimizing manufacturing costs and regulatory risks.

Key excipients in similar OTC formulations include microcrystalline cellulose, lactose monohydrate, magnesium stearate, and titanium dioxide. For UP AND UP, proprietary or optimized excipient blends may be applied to enhance disintegration rates or improve taste masking.

Formulation considerations:

  • Stability: Ensuring active ingredient protection from moisture, oxygen, and light.
  • Bioavailability: Facilitating rapid dissolution or controlled release.
  • Manufacturability: Compatibility with compression or encapsulation processes.
  • Regulatory compliance: Use of excipients permitted by FDA and other authorities.

What are the commercial opportunities related to excipient strategy?

Efficient excipient formulation can lead to competitive advantages in licensing, shelf life, and patient adherence, which drive sales. Opportunities include:

Cost reduction through optimized excipients

Using high-yield, low-cost excipients minimizes manufacturing expenses. For example, substituting expensive stabilizers with more effective alternatives can improve profit margins.

Differentiation via formulation innovation

Incorporating novel excipients, such as taste-masking agents or disintegration enhancers, improves patient experience. This innovation can justify premium pricing and market share growth.

Regulatory and patent barriers

Developing proprietary excipient blends or delivery mechanisms can create barriers to entry, allowing for patent extensions or exclusivities.

Market expansion through formulation flexibility

A versatile excipient framework supports product line extensions, such as extended-release versions or formulations suitable for different demographics (e.g., pediatric formulations).

Supply chain stability

Securing long-term contracts for critical excipients can reduce vulnerability to supply disruptions, ensuring consistent product availability.

Competitive landscape

Leading OTC brands leverage excipient innovation for differentiation. For example, Tylenol and Advil formulations incorporate excipients that optimize absorption and reduce side effects. Walgreens' UP AND UP can adopt similar strategies, focusing on cost-effective, innovative excipients to boost market positioning.

Regulatory outlook

Regulatory agencies, including the FDA, specify permissible excipients and maximum allowed quantities. Staying compliant while optimizing excipients for stability and bioavailability is vital. Patentability of excipient formulations hinges on novelty and inventive step, which can extend exclusivity periods.

Summary of key excipient considerations

Aspect Details
Common excipients in OTC drugs Microcrystalline cellulose, lactose, magnesium stearate, titanium dioxide
Regulatory constraints FDA excipient list, maximum usage limits
Innovation potential Taste masking, controlled release, stability enhancers
Cost considerations Use of bulk, synthetic, or novel excipients to reduce costs
Patent strategies Novel excipient blends, unique delivery mechanisms

Key Opportunities

  • Develop proprietary excipient blends to extend patent life.
  • Invest in formulation research to optimize absorption and patient experience.
  • Secure supply agreements for critical ingredients.
  • Leverage formulation agility for product line expansion.
  • Explore novel excipients that provide regulatory advantages or improved performance.

Key Takeaways

  • Excipient choice influences product stability, bioavailability, and manufacturing costs.
  • Strategic formulation can create competitive advantages via patent protection and market differentiation.
  • Cost-effective excipient optimization improves margins.
  • Regulatory compliance remains a critical factor, with scope for patentable innovation.
  • Supply chain stability for excipients ensures consistent product availability.

FAQs

  1. How does excipient choice affect product shelf life?
    Excipients such as stabilizers prevent active ingredient degradation, extending shelf life.

  2. Can innovation in excipients lead to patent protection?
    Yes, novel excipient blends or delivery mechanisms can qualify for patent protection.

  3. What are common regulatory challenges in excipient formulation?
    Ensuring excipient approval, permissible quantities, and manufacturing standards compliance.

  4. How can excipient optimization improve patient adherence?
    By enhancing taste, disintegration, and dosing convenience.

  5. What role do excipients play in cost management?
    Selecting affordable, high-performance excipients reduces manufacturing costs and improves margins.


References

[1] US Food and Drug Administration. (2022). Guidance for Industry: Excipients in FDA-regulated Products.
[2] Caleja, C., Barros, L., & Ferreira, I. C. F. R. (2017). Functional Properties of Excipients in Pharmaceutical Formulations. Pharmaceutics, 9(4), 56.
[3] Sharma, G., et al. (2019). Advances in Pharmaceutical Excipients: Role, Quality, and Regulatory Aspects. Current Drug Delivery, 16(5), 406-433.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.